Sign In
Buy IONS
$73.82
+0.85 (+1.16%)
At Close: Jun 03, 2026
Ionis Pharmaceuticals, Inc. (IONS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
06:11pm, Tuesday, 09'th Sep 2025
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 12:20 PM EDT Company Participants Brett Monia - Founder, CEO & Director Conference
Ionis Pharmaceuticals To Expedite Development Of Rare Neurological Disease Candidate With FDA Breakthrough Status
01:51pm, Tuesday, 09'th Sep 2025
On Tuesday, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to Ionis Pharmaceuticals Inc.'s IONS ION582 for Angelman syndrome (AS), a rare neurological disorder.
Ionis receives U.S. FDA Breakthrough Therapy designation for ION582 in Angelman syndrome
07:00am, Tuesday, 09'th Sep 2025
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ION582 fo
Ionis Pharmaceuticals, Inc. (IONS) Presents At H.C. Wainwright 27th Annual Global Investment Conference (Transcript)
05:33pm, Monday, 08'th Sep 2025
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) H.C. Wainwright 27th Annual Global Investment Conference September 8, 2025 3:00 PM EDT Company Participants Brett Monia - Founder, CEO & Director Conference
Ionis to host investors and analysts for Innovation Day 2025
04:00pm, Monday, 08'th Sep 2025
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it will host Ionis Innovation Day on Tuesday, October 7, 2025, in New York. The agenda will feature p
Ionis Pharmaceuticals, Inc. (IONS) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
01:47pm, Thursday, 04'th Sep 2025
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 10:15 AM EDT Company Participants Brett Monia - Founder, CEO & Director Conference Call
IONS Hits 52-Week High on Tryngolza's Success in Lowering Triglyceride
11:51am, Wednesday, 03'rd Sep 2025
Ionis surges to a 52-week high after Tryngolza shows strong triglyceride reductions and cuts acute pancreatitis risk by 85% in late-stage studies.
Is The 35% Rally In IONS Stock Just The Beginning?
10:41am, Wednesday, 03'rd Sep 2025
Ionis Pharmaceuticals' stock jumped 35% on September 2, 2025, after positive late-stage clinical trial results for olezarsen, a therapy for severe hypertriglyceridemia (sHTG). Investor enthusiasm is a
Ionis to present at upcoming investor conferences
04:00pm, Tuesday, 02'nd Sep 2025
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: 2025 Wells Fargo
Ionis Pharmaceuticals, Inc. (IONS) Positive CORE And CORE2 Topline Results (Transcript)
12:26pm, Tuesday, 02'nd Sep 2025
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Positive CORE and CORE2 Topline Results Company Participants D. Walke - Senior Vice President of Investor Relations Brett Monia - Founder, CEO & Director Sot
Ionis Pharmaceuticals stock rockets 31% to new 52-week high on breakthrough news
11:17am, Tuesday, 02'nd Sep 2025
Ionis Pharmaceuticals stock jumped 31% on Tuesday hitting a new 52-week high after breakthrough news that lit up investor interest and boosted confidence across the biotech sector.
Ionis Pharma's Investigational Drug Shows Promise For Triglyceride And Pancreatitis Reduction
10:38am, Tuesday, 02'nd Sep 2025
Ionis Pharmaceuticals, Inc. IONS on Tuesday released topline results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen for severe hypertriglyceridemia (sHTG).
Ionis shares jump after drug lowers blood fat levels in advanced trials
09:25am, Tuesday, 02'nd Sep 2025
Ionis Pharmaceuticals' shares surged on Tuesday before the bell after the drugmaker said its experimental treatment significantly reduced levels of blood fats called triglycerides and reduced pancreat
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive topline results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen in people with sever
mRNA Biotechs - Long-Term Value Risks Abound
06:20am, Thursday, 28'th Aug 2025
mRNA vaccine companies are overhyped post-pandemic, facing scientific, operational, and regulatory headwinds that limit long-term investment appeal. Scientific and business risks, including delivery c
